Cue Biopharma awards 100K options to executive
Cue Biopharma, Inc. reported that Chief Development Officer Daniel G. Baker received a grant of stock options covering 100,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cue Biopharma, Inc. reported that Chief Development Officer Daniel G. Baker received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.29 per share and expire on April 8, 2036.
The award vests over four years, with 25% of the options vesting on the first anniversary of the grant date and the remaining options vesting in equal semi-annual installments thereafter. Following this grant, Baker holds 100,000 stock options directly.
Insider Trade Summary
Grant/Award: 100,000 shares
Grant/Award
1 txn
Insider
Baker Daniel G.
Role
CHIEF DEVELOPMENT OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 100,000 contracts (Direct)
Footnotes (1)
- F1. This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter.
Key Figures
Option grant size: 100,000 options
Exercise price: $0.29 per share
Expiration date: April 8, 2036
+3 more
6 metrics
Option grant size
100,000 options
Stock Option (right to buy) awarded to CDO Daniel G. Baker
Exercise price
$0.29 per share
Conversion or exercise price of granted stock options
Expiration date
April 8, 2036
Option term end date for this grant
Underlying shares
100,000 shares
Common Stock underlying the stock option grant
Post-grant derivative holdings
100,000 options
Total derivative securities held after transaction
Initial vesting
25% after 1 year
Portion of options vesting on first anniversary of grant date
Key Terms
Stock Option (right to buy), exercise price, vesting, Common Stock, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 0.2900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
expiration date financial
"expiration_date: 2036-04-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cue Biopharma (CUE) report for Daniel G. Baker?
Cue Biopharma reported that Chief Development Officer Daniel G. Baker received a grant of stock options for 100,000 shares of Common Stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.
What is the exercise price of Daniel G. Baker’s new Cue Biopharma stock options?
The granted stock options have an exercise price of $0.29 per share. This means Baker can, once vested and until expiration, purchase Cue Biopharma Common Stock at $0.29 per share regardless of the market price at that time.
How do Daniel G. Baker’s Cue Biopharma options vest over time?
The options vest over four years. 25% of the award vests on the first anniversary of the grant date, and the remaining 75% vests in equal semi-annual installments thereafter, aligning the award with multi-year service at the company.
When do Daniel G. Baker’s Cue Biopharma stock options expire?
The stock options expire on April 8, 2036. After that expiration date, any unexercised portion of the 100,000-share option grant will lapse, and Baker will no longer be able to purchase shares under this specific option award.
How many Cue Biopharma derivative securities does Daniel G. Baker hold after this Form 4?
Following this grant, Daniel G. Baker holds 100,000 stock options directly, each tied to one share of Cue Biopharma Common Stock. The filing does not list additional derivative positions in the derivative holdings summary for this reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates